Adverse effects of clinical trial data transparency: Should we worry?

13 julio 2015

New legislation forces drug developers to disclose most of their clinical trials data when applying for approval of a new drug. Many will probably think that this is a good idea. However, too much transparency in drug development might be problematic, according to a new report. The report warns that the new regulations might make it difficult for companies to patent new medical uses for known drugs. Without sufficient alternatives, this may inhibit the full development of new medical uses towards market approval.img src=»» height=»1″ width=»1″ alt=»»/